

SUPPLEMENTAL INFORMATION:

**Individual Serum Saturated Fatty Acids and Markers of Chronic Subclinical Inflammation:
The Insulin Resistance Atherosclerosis Study (IRAS)**

Ingrid D. Santaren¹, Steven M. Watkins², Angela D. Liese³, Lynne E. Wagenknecht⁴, Marian J. Rewers⁵,
Steven M. Haffner⁶, Carlos Lorenzo⁶, Andreas Festa⁷, Richard P. Bazinet¹, Anthony J. Hanley^{1,8,*}

¹Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada,
M5S 3E2

²Metabolon Inc., West Sacramento, CA, 95835

³Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South
Carolina, Columbia, SC 29201

⁴Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC 27157

⁵Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus,
Aurora, CO 80045

⁶Division of Clinical Epidemiology, University of Texas Health Sciences Center, San Antonio, TX 78229

⁷1st Medical Department, LK Stockerau, Niederösterreich, Austria, 2000

⁸Leadership Sinai Center for Diabetes, Mount Sinai Hospital, Toronto, ON, Canada, M5G 1X5

Variable	Current study	Excluded participants	p value
n	555	1069	
Age (years)	54.5±8.63	56.24±8.33	0.0001
Sex, n (%)			0.8100
Males	248 (44.68)	471 (44.06)	
Females	307 (55.32)	598 (55.94)	
Ethnicity, n (%)			0.0161
Non-Hispanic White	232 (41.8)	380 (35.55)	
African American	137 (24.68)	327 (30.59)	
Hispanic	186 (33.51)	362 (33.86)	
Study center, n (%)			0.0019
Los Angeles	146 (26.31)	38 (19.59)	
Oakland	115 (20.72)	51 (26.29)	
San Antonio	126 (22.7)	64 (32.99)	
San Luis Valley	168 (30.27)	41 (21.13)	

Supplemental Table S1: Differences in participant characteristics included and excluded in the study sample. Exclusion criteria were type 2 diabetes at baseline, missing saturated fatty acid and inflammatory marker measures, and C-reactive protein concentrations ≥ 10 mg/L. Data are expressed as mean \pm SD or n(%).